Satellite Banner
Informatics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Life Technologies Announces First Quarter 2013 Results

Published: Friday, May 03, 2013
Last Updated: Friday, May 03, 2013
Bookmark and Share
Revenue increased 2.5% to $963 million.

Life Technologies Corporation announced results for its first quarter ended March 31, 2013.  Revenue for the first quarter was $963 million, an increase of 2.5 percent over the $939 million reported for the first quarter of 2012.  Excluding the impact of currency, revenue growth for the quarter was 4.4 percent compared to the same period of the prior year.

"We had a successful start to the year with strength across our Applied Sciences and Genetic Analysis business groups, including double digit growth in both our Bioproduction and Forensics businesses, which drove revenues and earnings growth above our guidance expectations," said Gregory T. Lucier, chairman and chief executive officer of Life Technologies.  "Our end markets remained in line with our expectations, with strength in emerging markets and across much of Asia, and continued cautious spending in the United States and Europe, as expected.

"During the quarter, we continued our rapid pace of innovation with new bioinformatics tools for Ion Torrent and software for our synthetic biology business.  We also continued to execute against our strategy to expand in growth and emerging markets as we entered into new collaborations in stem cells, Rapid DNA products, and acquired our reagent distributor in South Korea."

Lucier continued, "On April 15, Life Technologies and Thermo Fisher Scientific announced that the two companies had signed a definitive agreement under which Thermo Fisher will acquire Life for $76.00 in cash per fully diluted common share, or approximately $13.6 billion. We look forward to joining forces with the outstanding team at Thermo Fisher, which shares our commitment to customers, employees and shareholders."

Life Technologies reported results compared to the quarter ended March 31, 2012.  Results are non-GAAP unless indicated otherwise. A full reconciliation of the non-GAAP measures to GAAP can be found in the tables of today's press release.

Analysis of First Quarter 2013 Results

•    First quarter revenue increased 2.5 percent over the prior year, or 4.4 percent excluding the impact of currency.  Revenue growth for the quarter was driven by strong sales from the Ion Torrent, Bioproduction and Forensics businesses, partially offset by expected declines in SOLiD® sales and lower Research Consumables and capital equipment sales primarily due to the expected slowdown in the U.S. as the threat of sequestration impacted customer buying patterns.
•    Gross margin in the first quarter was 66.2 percent, approximately 40 basis points lower than the same period of the prior year. Gross margin was negatively impacted by a higher mix of Ion Torrent instrument sales, Bioproduction sales and unfavorable currency rates, partially offset by manufacturing productivity and royalties including licensing agreements.
•    Operating margin was 29.4 percent in the first quarter, approximately 80 basis points lower than the same period of the prior year. Operating margin was primarily impacted by lower gross margin and planned investments in emerging markets and molecular diagnostics.
•    The tax rate was 26.2 percent for the first quarter.
•    First quarter EPS increased 8 percent to $1.07.
•    Diluted weighted shares outstanding were 174.5 million in the first quarter, a decrease of 8.6 million shares over the prior year.  The decrease was a result of the company's share repurchase program, partially offset by shares issued for employee stock plans.  The company repurchased $105 million or 2 million shares in the first quarter.
•    Cash flow from operating activities for the first quarter was $135 million. First quarter capital expenditures were $24 million, offset by $37 million of cash proceeds from the sale of assets, resulting in free cash flow of $148 million.  The company ended the quarter with $293 million in cash and short-term investments.

Business Group and Regional Highlights

•    Research Consumables revenue was $409 million in the first quarter, a decrease of 3 percent compared to the prior year.  Excluding the impact from currency, revenue for the business group declined 1 percent. The decline in growth for the quarter was primarily driven by cautious spending in the U.S. and Europe and a tough comparison to prior year in Japan, which benefited from stimulus spending in Q1 2012.
•    Genetic Analysis revenue was $365 million in the first quarter, an increase of 3 percent over the same period last year. Excluding the impact from currency, revenue increased 5 percent. Growth for the quarter was primarily driven by an increase in our Ion Torrent business and royalties including licensing agreements, partially offset by lower CE instrument sales and an expected decline in SOLiD product sales.
•    Applied Sciences revenue was $189 million in the first quarter, an increase of 17 percent over the same period last year. Excluding the impact from currency, revenue increased 19 percent. Growth for the quarter was primarily driven by sales in Bioproduction and Forensics products.
•    Regional revenue growth rates excluding currency for the first quarter compared to the same quarter of the prior year were as follows: the Americas grew 5 percent, Europe grew 3 percent, Asia Pacific grew 10 percent and Japan grew 1 percent.  The Americas benefited from increased sales in Ion Torrent, Forensics, Bioproduction and higher royalties including licensing agreements.  Europe saw growth in Forensics and Bioproduction, offset by lower Research Consumables.  Asia Pacific grew across all business groups primarily due to Ion Torrent, Research Consumables, and Bioproduction.  Japan growth was primarily due to Ion Torrent and Bioproduction sales, offset by lower sales from government stimulus programs that took place in the same period last year.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Thermo Acquisition Approved by Life Technologies Stockholders
Company announced that its stockholders voted to adopt the previously announced merger agreement.
Thursday, August 22, 2013
Life Technologies Acquires Compendia Bioscience
Acquisition of a preeminent cancer bioinformatics company enhance's Life's diagnostic development capabilities across multiple platforms
Sunday, November 11, 2012
Life Technologies introduces Ion AmpliSeq™ Community Panels
Ion AmpliSeq™ Community Panels leverages the expertise of scientific thought leaders and the Ion Community to create gene panels for conditions ranging from cancer to inherited diseases.
Wednesday, November 07, 2012
Life Technologies Acquires Compendia Bioscience
Acquisition expands Life Technologies' ability to drive progress in personalized medicine
Sunday, October 14, 2012
Life Technologies Names Alan Sachs as Head of Global Research and Development
Sachs brings more than 20 years of experience as a research scientist and a leader in developing innovative scientific platforms.
Wednesday, February 01, 2012
Scientific News
Improving Drug Production with Computer Model
A model has been developed that can be used to improve and accelerate the production of biotherapeutics, cancer drugs, and vaccines.
Accelerating the Detection of Foodborne Bacterial Outbreaks
The speed of diagnosis of foodborne bacterial outbreaks could be improved by a new technique developed by researchers at the Georgia Institute of Technology.
Largest Resource of Protein-Protein Interactions
Researchers have developed the largest ever database of protein-protein interactions.
NVIDIA Awards $400k to Trailblazers in Cancer Research
NVIDIA Foundation furthers research that could lead to new and more targeted treatments with investments.
Computers Learn to Recognize Molecules That Can Enter Cells
Researchers discover peptides with antimicrobial properties, but also that many known human proteins also had this ability.
Big Data for Infectious Disease Surveillance
NIH-led effort examines use of big data from health records and other digital sources for uses in infectious disease surveillance.
Clinical Screening Test for Gut Health Developed
uBiome has created an entirely new approach to support the clinical diagnosis of gut health conditions.
Computational Tool May Speed Drug Discovery
Scientists are able to see beyond static images of proteins with the help of a new computational tool.
Scientists Develop a Novel Method to Benchmark and Improve the Performance of Protein Measurement Techniques
A wide range of laboratories around the world are benefiting from this work, which enables researchers to analyze or compare the results of quantitative proteomics assays in a standardized way.
Uncovering the Cellular Environment
Researchers have shown how molecules move within a crowded bacterial cell using Japan's K supercomputer.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!